4//SEC Filing
Riggs Josh 4
Accession 0001493152-23-021059
CIK 0001642380other
Filed
Jun 12, 8:00 PM ET
Accepted
Jun 13, 4:05 PM ET
Size
8.1 KB
Accession
0001493152-23-021059
Insider Transaction Report
Form 4
Riggs Josh
CEO and President
Transactions
- Award
Option to Purchase Common Stock
2023-06-09+350,000→ 350,000 totalExercise: $0.21Exp: 2033-06-09→ Common Stock (350,000 underlying) - Award
Option to Purchase Common Stock
2023-06-09+800,000→ 800,000 totalExercise: $0.21Exp: 2033-06-09→ Common Stock (800,000 underlying)
Footnotes (2)
- [F1]25% of the options will vest and thereby be exercisable after one year of continuous service from the effective date of grant, and the balance will vest and thereby be exercisable in 36 equal monthly installments commencing one year after the date of grant, subject to continuous service through the applicable vesting date.
- [F2]The options will vest and thereby be exercisable on December 31, 2025, based on achievement of certain specified targets with respect to the 30-day volume-weighted average price of Company's common stock, measured as of the end of each full calendar month up through December 31, 2025, subject to continuous services through December 31, 2025.
Documents
Issuer
Oncocyte Corp
CIK 0001642380
Entity typeother
Related Parties
1- filerCIK 0001956391
Filing Metadata
- Form type
- 4
- Filed
- Jun 12, 8:00 PM ET
- Accepted
- Jun 13, 4:05 PM ET
- Size
- 8.1 KB